Response of Neuragen® Active Ingredient to Spontaneous Pain Associated with Post-Herpetic Neuralgia.
Results shown below indicate that nearly two-thirds of patients responded with at least a 20-40% reduction in pain. Of these, more than 1 in 5 patients experienced a greater that 60% reduction in pain, with some experiencing an almost total reduction in severe chronic pain.
Peripheral Neuropathy Effectiveness Survey Results
Background:
Health Practitioners with patients suffering with diabetic peripheral neuropathy were invited to participate. Efficacy was measured primarily by reduction in pain intensity over the first six hours, compared with the pain intensity before the application.
Results:
Overall 29 patients satisfactorily completed the survey. Of these, 20 patients (69%) noted some improvement in pain, with 17 patients (59%) noting a remarkable 50-100% improvement, usually within minutes of applying Neuragen topically. This rate of efficacy is comparable or better than the #1 prescribed pharmaceutical for neuropathic pain, Neurontin®, which claims to benefit 50% of patients.
